Clinical Trials on Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

Total 678 results

Mayo Clinic
National Cancer Institute (NCI)

Completed

Samarium Sm 153 Lexidronam Pentasodium and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma

Multiple Myeloma and Plasma Cell Neoplasm

United States
Mayo Clinic
National Cancer Institute (NCI)

Completed

Bevacizumab in Treating Patients With Relapsed or Refractory Multiple Myeloma

Multiple Myeloma and Plasma Cell Neoplasm

United States
Mayo Clinic

Withdrawn

Nilotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia or Blastic Phase Chronic Myelogenous Leukemia

B-cell Adult Acute Lymphoblastic Leukemia | Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Philadelphia Chromosome Positive Adult Precursor Acute Lymphoblastic Leukemia | Untreated Adult Acute Lymphoblastic Leukemia | Blastic Phase Chronic Myelogenous Leukemia

United States
Case Comprehensive Cancer Center
National Cancer Institute (NCI)

Terminated

Study of Natural Killer Cells in Bone Marrow and Blood Samples From Patients With and Without Hematologic Cancer

Leukemia | Multiple Myeloma and Plasma Cell Neoplasm

United States
Institute of Hematology & Blood Diseases Hospital

Unknown

a Clinical Trial of Efficacy and Safety of the Holistic Treatment of Young High-risk Multiple Myeloma Patients

Multiple Myeloma | Plasma Cell Leukemia | Extramedullary Plasmacytoma | Loss of Chromosome 17p | t(14;16) | t(4;14) | Complex Karyotype | T(14;20) | 1Q21 Amplification

China
CTI BioPharma
National Cancer Institute (NCI)

Terminated

Arsenic Trioxide and Dexamethasone in Treating Patients With Recurrent or Refractory Stage II or Stage III Multiple Myeloma

Multiple Myeloma and Plasma Cell Neoplasm

United States
University of Maryland, Baltimore
University of Maryland Greenebaum Cancer Center

Completed

Chemotherapy and Peripheral Stem Cell Transplantation Followed By Immunotherapy in Treating Patients With Multiple Myeloma

Infection | Multiple Myeloma and Plasma Cell Neoplasm

United States
Jan Walewski

Completed

Dendritic Cell Vaccine in Treating Patients With Indolent B-Cell Lymphoma or Multiple Myeloma

Lymphoma | Multiple Myeloma and Plasma Cell Neoplasm

Poland
University of Miami
National Cancer Institute (NCI)

Completed

Arsenic Trioxide Plus Vitamin C in Treating Patients With Recurrent or Refractory Multiple Myeloma

Multiple Myeloma and Plasma Cell Neoplasm

United States
Case Comprehensive Cancer Center
National Cancer Institute (NCI)

Completed

Brostallicin in Treating Patients With Recurrent or Refractory Multiple Myeloma

Multiple Myeloma and Plasma Cell Neoplasm

United States
Northwestern University
National Cancer Institute (NCI)

Completed

Tocladesine in Treating Patients With Recurrent or Refractory Multiple Myeloma

Multiple Myeloma and Plasma Cell Neoplasm

United States
Medical Research Council

Unknown

Combination Chemotherapy and Interferon Alfa With or Without Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Myeloma

Multiple Myeloma and Plasma Cell Neoplasm

United Kingdom
National Cancer Institute (NCI)

Completed

Imatinib Mesylate and Decitabine in Treating Patients With Chronic Myelogenous Leukemia

Accelerated Phase Chronic Myelogenous Leukemia | Childhood Chronic Myelogenous Leukemia | Relapsing Chronic Myelogenous Leukemia | Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Blastic Phase Chronic Myelogenous Leukemia

United States
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Arsenic Trioxide and Imatinib Mesylate in Treating Patients With Accelerated Phase or Blastic Phase Chronic Myelogenous Leukemia or Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

Leukemia

United States
National Cancer Institute (NCI)

Active, not recruiting

Ulixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial)

Advanced Malignant Solid Neoplasm | Refractory Malignant Solid Neoplasm | Recurrent Ewing Sarcoma | Recurrent Hepatoblastoma | Recurrent Histiocytic and Dendritic Cell Neoplasm | Recurrent Langerhans Cell Histiocytosis | Recurrent Malignant Germ Cell Tumor | Recurrent Malignant Solid Neoplasm | Recurrent... and other conditions

United States, Puerto Rico
H. Lee Moffitt Cancer Center and Research Institute
Bristol-Myers Squibb; SmithKline Beecham

Completed

Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma

Multiple Myeloma | Plasma Cell Neoplasm

United States
Southwest Oncology Group
National Cancer Institute (NCI)

Completed

S0232 Dexamethasone With or Without Lenalidomide in Treating Patients With Previously Untreated Stage I, Stage II, or Stage III Multiple Myeloma

Multiple Myeloma | Plasma Cell Neoplasm

United States
Mayo Clinic
National Cancer Institute (NCI)

Completed

Samarium Sm 153 Lexidronam Pentasodium Combined With Zoledronic Acid or Pamidronate in Treating Patients With Relapsed or Refractory Multiple Myeloma and Bone Pain

Pain | Multiple Myeloma and Plasma Cell Neoplasm

United States
Oncotherapeutics

Withdrawn

Melphalan, Arsenic Trioxide, and Ascorbic Acid in Treating Patients With Relapsed or Refractory Multiple Myeloma

Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Plasma Cell Neoplasm

United States
Northwestern University
National Cancer Institute (NCI)

Completed

Melphalan Followed by Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma

Multiple Myeloma and Plasma Cell Neoplasm

United States
Memorial Sloan Kettering Cancer Center

Active, not recruiting

A Study of Lenalidomide and CC-486 With Radiation Therapy in Patients With Plasmacytoma

Multiple Myeloma | Plasmacytoma | Plasmacytoma of Bone

United States
Shenzhen Geno-Immune Medical Institute
The No.2 Clinical Hospital of the Ministry of Health

Recruiting

Engineered Dendritic Cell Vaccines for Multiple Myeloma

Multiple Myeloma or Plasmacytoma

China, Russian Federation
National Cancer Institute (NCI)

Completed

Vaccine Therapy in Treating Patients With Multiple Myeloma

Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Plasma Cell Neoplasm

United States
Eastern Cooperative Oncology Group
National Cancer Institute (NCI)

Completed

Biological Therapy in Treating Patients With Multiple Myeloma That Has Recurred Following Bone Marrow Transplantation

Multiple Myeloma and Plasma Cell Neoplasm

United States
Sidney Kimmel Comprehensive Cancer Center at Johns...
National Cancer Institute (NCI)

Terminated

Interferon Alfa and Interleukin-6 in Treating Patients With Recurrent Multiple Myeloma

Multiple Myeloma and Plasma Cell Neoplasm

United States
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Terminated

Lenalidomide and Rituximab in Treating Patients With Recurrent and/or Refractory Multiple Myeloma

Multiple Myeloma and Plasma Cell Neoplasm

United States
LifeTime Pharmaceuticals

Unknown

Beta Alethine in Treating Patients With Myeloma

Multiple Myeloma and Plasma Cell Neoplasm | Precancerous Condition

United States
University of Arkansas
National Cancer Institute (NCI)

Completed

Suramin in Treating Patients With Refractory or Relapsed Multiple Myeloma or Castleman's Disease

Multiple Myeloma and Plasma Cell Neoplasm

United States
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Completed

Peripheral Stem Cell Transplant in Treating Patients With Multiple Myeloma

Multiple Myeloma | Plasma Cell Neoplasm

United States
National Cancer Institute (NCI)

Completed

6-Hydroxymethylacylfulvene in Treating Patients With Refractory Myelodysplastic Syndrome, Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, or Blastic Phase Chronic Myelogenous Leukemia

Myelodysplastic Syndromes | Leukemia

United States
The Republican Research and Practical Center for...
Belarusian State Medical University

Completed

Dendritic Cell Immunotherapy for the Patients With Pancreatic Cancer

Pancreatic Neoplasms | Dendritic Cells

Belarus
Lithuanian University of Health Sciences

Unknown

Comparable Investigation of One Fraction Radiotherapy and Multifraction Radiotherapy in Patients With Multiple Myeloma.

Multiple Myeloma and Malignant Plasma Cell Neoplasms

Lithuania
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Melphalan and Autologous Stem Cell Transplant Followed By Bortezomib and Dexamethasone in Treating Patients With Previously Untreated Systemic Amyloidosis

Multiple Myeloma and Plasma Cell Neoplasm

United States
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Completed

Omega-3 Fatty Acids in Treating Patients With Advanced Cancer Who Have Significant Weight Loss

Lymphoma | Leukemia | Multiple Myeloma and Plasma Cell Neoplasm

United States
The Cleveland Clinic

Withdrawn

Arsenic Trioxide, Ascorbic Acid, Dexamethasone, and Thalidomide in Treating Patients With Multiple Myeloma

Stage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Plasma Cell Neoplasm

United States
Ohio State University Comprehensive Cancer Center
Merck Sharp & Dohme LLC

Completed

Vorinostat and Lenalidomide After Autologous Stem Cell Transplant in Treating Patients With Multiple Myeloma

Multiple Myeloma | Plasma Cell Neoplasm

United States
M.D. Anderson Cancer Center
Novartis

Completed

RAD001 in Relapsed or Refractory AML, ALL, CML in Blastic-Phase, Agnogenic Myeloid Metaplasia, CLL, T-Cell Leukemia, or Mantle Cell Lymphoma

Leukemia | Myelofibrosis | Mantle Cell Lymphoma

United States
European Myeloma Network
Janssen, LP

Active, not recruiting

Daratumumab Combined With Bortezomib, Cyclophosphamide and Dexamethasone for the Treatment of Multiple Myeloma Patients Presenting With Extramedullary Disease (EMN19)

Multiple Myeloma | Extramedullary Plasmacytoma

Turkey, Italy, Greece
Beijing Chao Yang Hospital
Peking University People's Hospital

Unknown

CDD Plus Bortezomib or CDDin Relapsed or Refractory Multiple Myeloma With Extramedullary Plasmacytoma

Extramedullary Plasmacytoma

China
Hoag Memorial Hospital Presbyterian
Cancer Biotherapy Research Group

Withdrawn

Monoclonal Antibody Therapy or Biological Therapy in Treating Patients With Chronic Lymphocytic Leukemia or Multiple Myeloma in Remission After Chemotherapy

Leukemia | Multiple Myeloma and Plasma Cell Neoplasm

United States
University of Medicine and Dentistry of New Jersey
National Cancer Institute (NCI)

Terminated

Irradiated Donor Lymphocytes and Rituximab in Treating Patients With Relapsed or Refractory Lymphoproliferative Disease

Lymphoma | Leukemia | Multiple Myeloma and Plasma Cell Neoplasm

United States
Southwest Oncology Group
National Cancer Institute (NCI); Eastern Cooperative Oncology Group

Completed

SWOG-9239 Reduction of Immunosuppression Plus Interferon Alfa and Combination Chemotherapy in Treating Patients With Malignant Tumors That Develop After Organ Transplant

Lymphoma | Multiple Myeloma and Plasma Cell Neoplasm

United States
Mayo Clinic
University of Iowa

Completed

Sorafenib and Everolimus in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma

Lymphoma | Multiple Myeloma and Plasma Cell Neoplasm

United States
Mayo Clinic
National Cancer Institute (NCI)

Completed

CC-4047 and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma or Amyloidosis

Multiple Myeloma and Plasma Cell Neoplasm

United States
Sidney Kimmel Comprehensive Cancer Center at Johns...
National Cancer Institute (NCI)

Completed

Interleukin-2 Following Bone Marrow Transplantation in Treating Patients With Hematologic Cancer

Lymphoma | Leukemia | Multiple Myeloma and Plasma Cell Neoplasm

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Completed

Panobinostat and Everolimus in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma

Lymphoma | Multiple Myeloma and Plasma Cell Neoplasm

United States
Temple University

Completed

High-Dose Melphalan Followed by Peripheral Stem Cell Transplant in Treating Patients With Amyloidosis

Multiple Myeloma and Plasma Cell Neoplasm

United States
Emory University

Withdrawn

Patient-Driven Transfusion Thresholds in Hematological Disorders: A Pilot Study

Hematopoietic and Lymphoid Cell Neoplasm | Leukemia | Anemia | Myelodysplastic Syndrome | Aplastic Anemia | Bone Marrow Failure

United States
National Cancer Institute (NCI)

Completed

CCI-779 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndromes, or Chronic Myelogenous Leukemia in Blastic Phase

Chronic Myelomonocytic Leukemia | Recurrent Adult Acute Myeloid Leukemia | Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities | Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) | Adult Acute Myeloid Leukemia With t(16;16)(p13;q22) | Adult Acute Myeloid Leukemia With t(8;21)(q22;q22) and other conditions

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Hu8F4 in Treating Patients With Advanced Hematologic Malignancies

Hematopoietic and Lymphoid Cell Neoplasm | Myelofibrosis | Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome | Secondary Acute Myeloid Leukemia | Recurrent Acute Myeloid Leukemia | Recurrent Chronic Myelomonocytic Leukemia | Refractory Chronic Myelomonocytic Leukemia | High Risk... and other conditions

United States

Clinical Trials on Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Congo, DR of

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations